Dietary supplement for insulin-resistant diabetics

• US 5,124,360 A
• Filed: 03/21/1991
• Issued: 06/23/1992
• Est. Priority Date: 03/08/1989
• Status: Expired due to Term

• Current Assignee: University of Virginia Patent Foundation (University of Virginia)
• Original Assignee: University of Virginia Patent Foundation (University of Virginia)
• Inventors: Larner, Joseph, Kennington, Alison
• Primary Examiner(s): Ivy, C. Warren
• Assistant Examiner(s): CHANG, CELIA C
• Application Number:
  US07/672,778
• Time in Patent Office: 460 Days
• Field of Search: 514/738, 514/866
• US Class Current: 514/738
• CPC Class Codes: A23L 29/37 Sugar alcohols
• CPC Class Codes: A61K 31/047 having two or more hydroxy groups, e.g. sorbitol
• CPC Class Codes: A61P 3/00 Drugs for disorders of the metabolism of the blood or the extracellular fluid A61P7/00
• CPC Class Codes: A61P 3/08 for glucose homeostasis pancreatic hormones A61P5/48
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

A dietary supplement for the therapeutic treatment of those exhibiting clinical symptoms of insulin-resistant type II diabetes, and preventing the development of clinical symptoms in those genetically predisposed to the development of such symptoms, is provided by the administration of a dietary supplement comprising D-chiro-inositol. The dietary supplement is preferably administered orally, in vitamin-like amounts.

Claims

1. An oral composition of matter effective in the reduction of blood glucose level of a diabetic individual, consisting essentially of D-chiroinositol (DCI) in amounts sufficient to provide a therapeutic level in said individual, to achieve reduction of the blood glucose level upon administration to said individual.

2. The composition of claim 1, wherein said D-chiroinositol is present in amounts between 25 and 100 milligrams.

3. A method for the therapeutic treatment of an individual exhibiting type II, insulin-resistant diabetes, comprising orally administering to said individual an oral composition of matter effective in the reduction of blood glucose levels of a diabetic individual, consisting essentially of DCI, in amounts sufficient to provide a therapeutic level of DCI for reduction of the blood glucose level of said individual.

4. The method of claim 3, wherein said DCI is present in amounts of 25 mg/kg to 100 mg/kg.